Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15784730 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Chen J, et al. (2005) Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation. Blood 106, 328-37 15784730
Download Sites

S118-p - ER-alpha (human)
Orthologous residues
ER‑alpha (human): S118‑p, ER‑alpha (mouse): S122‑p, ER‑alpha (rat): S123‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site, phospho-antibody
 Relevant cell lines - cell types - tissues:  BAEC (endothelial), EA.hy 926 (endothelial), Rad91 ('muscle, smooth')
 Cellular systems studied:  cell lines
 Species studied:  cow, human
 Enzymes shown to modify site in vitro
Type Enzyme
PHOSPHATASE PPP2CB (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP2CB (human) co-immunoprecipitation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
PD98059, okadaic acid inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.